These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26274033)

  • 1. The 5-Year EFS of Multisystem LCH With Risk-Organ Involvement Is Suboptimal: A Single-center Experience From India.
    Totadri S; Bansal D; Trehan A; Srinivasan R; Varma N; Kakkar N; Saxena AK; Bhatia P
    J Pediatr Hematol Oncol; 2016 Jan; 38(1):e1-5. PubMed ID: 26274033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
    Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
    Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
    Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of adult multisystemic Langerhans cell histiocytosis with psoralen-UV-A, prednisolone, mercaptopurine, and vinblastine.
    von Stebut E; Schadmand-Fischer S; Bräuninger W; Kreft A; Doberauer C; Steinbrink K
    Arch Dermatol; 2008 May; 144(5):649-53. PubMed ID: 18490592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China.
    Su M; Gao YJ; Pan C; Chen J; Tang JY
    Pediatr Hematol Oncol; 2018; 35(7-8):385-392. PubMed ID: 30693828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.
    Tazi A; Lorillon G; Haroche J; Neel A; Dominique S; Aouba A; Bouaziz JD; de Margerie-Melon C; Bugnet E; Cottin V; Comont T; Lavigne C; Kahn JE; Donadieu J; Chevret S
    Orphanet J Rare Dis; 2017 May; 12(1):95. PubMed ID: 28532436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group.
    Gadner H; Heitger A; Grois N; Gatterer-Menz I; Ladisch S
    Med Pediatr Oncol; 1994; 23(2):72-80. PubMed ID: 8202045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Langerhans Cell Histiocytosis (LCH) in Egyptian Children: Does Reactivation Affect the Outcome?
    Sedky MS; Rahman HA; Moussa E; Taha H; Raafat T; Hassanein O
    Indian J Pediatr; 2016 Mar; 83(3):214-9. PubMed ID: 26133729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
    Minkov M
    Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Langerhans' cell histiocytosis: experience from a single center.
    Bansal D; Marwaha RK; Trehan A; Gupta V; Varma N
    Indian Pediatr; 2008 Aug; 45(8):685-8. PubMed ID: 18723913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Langerhans cell histiocytosis in children less than 2 years of age.
    Kusuma Kumary P; Priyakumari T; Chellam VG; James FV; Nair MK
    Indian Pediatr; 1999 Jan; 36(1):29-36. PubMed ID: 10709120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of children younger than 24 months with langerhans cell histiocytosis and bone involvement: a report from a single institution.
    Kamath S; Arkader A; Jubran RF
    J Pediatr Orthop; 2014 Dec; 34(8):825-30. PubMed ID: 25387157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
    Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution.
    Braier J; Chantada G; Rosso D; Bernaldez P; Amaral D; Latella A; Balancini B; Masautis A; Goldberg J
    Pediatr Hematol Oncol; 1999; 16(5):377-85. PubMed ID: 10505313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Langerhans cell histiocytosis of skull: a retrospective study of 18 cases.
    Zhang XH; Zhang J; Chen ZH; Sai K; Chen YS; Wang J; Ke C; Guo CC; Chen ZP; Mou YG
    Ann Palliat Med; 2017 Apr; 6(2):159-164. PubMed ID: 28061539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disseminated Langerhans cell histocytosis in children: treatment outcome.
    Kusumakumary P; James FV; Chellam VG; Ratheesan K; Nair MK
    Am J Clin Oncol; 1999 Apr; 22(2):180-3. PubMed ID: 10199456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
    Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
    Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical characteristics and treatment outcome of Langerhans cell histiocytosis: 22 years' experience of 154 patients at a single center.
    Lee JW; Shin HY; Kang HJ; Kim H; Park JD; Park KD; Kim HS; Park SH; Wang KC; Ahn HS
    Pediatr Hematol Oncol; 2014 Apr; 31(3):293-302. PubMed ID: 24397251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.